APO Research
Talk to an analyst

APO RESEARCH · REPORT

Conjugate Vaccine

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

Selected research

Market Structure

Global Conjugate Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025185 pages

Choose your research edition.

Industry ResearchConjugate Vaccine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Conjugate Vaccine Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Conjugate Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Conjugate Vaccine Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Conjugate Vaccine Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.

Market competition is intense. Pfizer, GSK, Sanofi, Merck, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accounted for 86.11% market share in 2019.

This report provides an overview of the global Conjugate Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Conjugate Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Conjugate Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Conjugate Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Conjugate Vaccine Segment by Company

Pfizer

GSK

Sanofi

Merck

Walvax Biotechnology

Royal (Wuxi) Bio-Pharmaceutical

Bharat Biotech

Zhifei Biologic

Conjugate Vaccine Segment by Type

Hib Vaccine

Meningococcal Vaccine

Pneumococcal Vaccine

Others

Conjugate Vaccine Segment by End Users

Children

Adult

Conjugate Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Conjugate Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Conjugate Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Conjugate Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Conjugate Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Conjugate Vaccine Industry Trends Table 2. Conjugate Vaccine Industry Drivers Table 3. Conjugate Vaccine Industry Opportunities and Challenges Table 4. Conjugate Vaccine Industry Restraints Table 5. Global Conjugate Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Conjugate Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Conjugate Vaccine Sales by Manufacturers (Million Unit) & (2021-2026) Table 8. Global Conjugate Vaccine Sales Market Share by Manufacturers Table 9. Global Conjugate Vaccine Average Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 10. Global Conjugate Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Conjugate Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Conjugate Vaccine Manufacturers, Product Type & Application Table 13. Global Conjugate Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Conjugate Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Hib Vaccine Table 17. Major Manufacturers of Meningococcal Vaccine Table 18. Major Manufacturers of Pneumococcal Vaccine Table 19. Major Manufacturers of Others Table 20. Global Conjugate Vaccine Sales by Type 2021 VS 2025 VS 2032 (Million Unit) Table 21. Global Conjugate Vaccine Sales by Type (2021-2026) & (Million Unit) Table 22. Global Conjugate Vaccine Sales by Type (2027-2032) & (Million Unit) Table 23. Global Conjugate Vaccine Sales Market Share by Type (2021-2026) Table 24. Global Conjugate Vaccine Sales Market Share by Type (2027-2032) Table 25. Global Conjugate Vaccine Revenue by Type 2021 VS 2025 VS 2032 (Million Unit) Table 26. Global Conjugate Vaccine Revenue by Type (2021-2026) & (Million Unit) Table 27. Global Conjugate Vaccine Revenue by Type (2027-2032) & (Million Unit) Table 28. Global Conjugate Vaccine Revenue Market Share by Type (2021-2026) Table 29. Global Conjugate Vaccine Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Children Table 31. Major Manufacturers of Adult Table 32. Global Conjugate Vaccine Sales by Application 2021 VS 2025 VS 2032 (Million Unit) Table 33. Global Conjugate Vaccine Sales by Application (2021-2026) & (Million Unit) Table 34. Global Conjugate Vaccine Sales by Application (2027-2032) & (Million Unit) Table 35. Global Conjugate Vaccine Sales Market Share by Application (2021-2026) Table 36. Global Conjugate Vaccine Sales Market Share by Application (2027-2032) Table 37. Global Conjugate Vaccine Revenue by Application 2021 VS 2025 VS 2032 (Million Unit) Table 38. Global Conjugate Vaccine Revenue by Application (2021-2026) & (Million Unit) Table 39. Global Conjugate Vaccine Revenue by Application (2027-2032) & (Million Unit) Table 40. Global Conjugate Vaccine Revenue Market Share by Application (2021-2026) Table 41. Global Conjugate Vaccine Revenue Market Share by Application (2027-2032) Table 42. Global Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032 (Million Unit) Table 43. Global Conjugate Vaccine Sales by Region (2021-2026) & (Million Unit) Table 44. Global Conjugate Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Conjugate Vaccine Sales Forecasted by Region (2027-2032) & (Million Unit) Table 46. Global Conjugate Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Million Unit) Table 48. North America Conjugate Vaccine Sales by Country (2021-2026) & (Million Unit) Table 49. North America Conjugate Vaccine Sales by Country (2027-2032) & (Million Unit) Table 50. Europe Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Million Unit) Table 51. Europe Conjugate Vaccine Sales by Country (2021-2026) & (Million Unit) Table 52. Europe Conjugate Vaccine Sales by Country (2027-2032) & (Million Unit) Table 53. Asia Pacific Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Million Unit) Table 54. Asia Pacific Conjugate Vaccine Sales by Country (2021-2026) & (Million Unit) Table 55. Asia Pacific Conjugate Vaccine Sales by Country (2027-2032) & (Million Unit) Table 56. South America, Middle East and Africa Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Million Unit) Table 57. South America, Middle East and Africa Conjugate Vaccine Sales by Country (2021-2026) & (Million Unit) Table 58. South America, Middle East and Africa Conjugate Vaccine Sales by Country (2027-2032) & (Million Unit) Table 59. Global Conjugate Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Conjugate Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Conjugate Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Conjugate Vaccine Revenue Market Share by Region (2021-2026) Table 63. Global Conjugate Vaccine Revenue Market Share by Region (2027-2032) Table 64. Pfizer Company Information Table 65. Pfizer Business Overview Table 66. Pfizer Conjugate Vaccine Sales (Million Unit), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Pfizer Conjugate Vaccine Product Portfolio Table 68. Pfizer Recent Development Table 69. GSK Company Information Table 70. GSK Business Overview Table 71. GSK Conjugate Vaccine Sales (Million Unit), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GSK Conjugate Vaccine Product Portfolio Table 73. GSK Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Conjugate Vaccine Sales (Million Unit), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sanofi Conjugate Vaccine Product Portfolio Table 78. Sanofi Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Conjugate Vaccine Sales (Million Unit), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Merck Conjugate Vaccine Product Portfolio Table 83. Merck Recent Development Table 84. Walvax Biotechnology Company Information Table 85. Walvax Biotechnology Business Overview Table 86. Walvax Biotechnology Conjugate Vaccine Sales (Million Unit), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Walvax Biotechnology Conjugate Vaccine Product Portfolio Table 88. Walvax Biotechnology Recent Development Table 89. Royal (Wuxi) Bio-Pharmaceutical Company Information Table 90. Royal (Wuxi) Bio-Pharmaceutical Business Overview Table 91. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales (Million Unit), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Portfolio Table 93. Royal (Wuxi) Bio-Pharmaceutical Recent Development Table 94. Bharat Biotech Company Information Table 95. Bharat Biotech Business Overview Table 96. Bharat Biotech Conjugate Vaccine Sales (Million Unit), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Bharat Biotech Conjugate Vaccine Product Portfolio Table 98. Bharat Biotech Recent Development Table 99. Zhifei Biologic Company Information Table 100. Zhifei Biologic Business Overview Table 101. Zhifei Biologic Conjugate Vaccine Sales (Million Unit), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Zhifei Biologic Conjugate Vaccine Product Portfolio Table 103. Zhifei Biologic Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Conjugate Vaccine Distributors List Table 107. Conjugate Vaccine Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Conjugate Vaccine Product Image Figure 2. Global Conjugate Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Conjugate Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Conjugate Vaccine Sales (2021-2032) & (Million Unit) Figure 5. Global Conjugate Vaccine Average Price (USD/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Conjugate Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Hib Vaccine Image Figure 9. Meningococcal Vaccine Image Figure 10. Pneumococcal Vaccine Image Figure 11. Others Image Figure 12. Global Conjugate Vaccine Sales by Type (2021 VS 2025 VS 2032) & (Million Unit) Figure 13. Global Conjugate Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Conjugate Vaccine Sales Market Share by Type (2021-2032) Figure 15. Global Conjugate Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (Million Unit) Figure 16. Global Conjugate Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Conjugate Vaccine Revenue Market Share by Type (2021-2032) Figure 18. Children Image Figure 19. Adult Image Figure 20. Global Conjugate Vaccine Sales by Application (2021 VS 2025 VS 2032) & (Million Unit) Figure 21. Global Conjugate Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Conjugate Vaccine Sales Market Share by Application (2021-2032) Figure 23. Global Conjugate Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (Million Unit) Figure 24. Global Conjugate Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Conjugate Vaccine Revenue Market Share by Application (2021-2032) Figure 26. North America Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 27. North America Conjugate Vaccine Sales Market Share by Country (2021-2032) Figure 28. U.S. Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 29. Canada Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 30. Mexico Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 31. Europe Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 32. Europe Conjugate Vaccine Sales Market Share by Country (2021-2032) Figure 33. Germany Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 34. France Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 35. U.K. Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 36. Italy Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 37. Netherlands Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 38. Asia Pacific Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 39. Asia Pacific Conjugate Vaccine Sales Market Share by Country (2021-2032) Figure 40. China Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 41. Japan Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 42. South Korea Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 43. Southeast Asia Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 44. India Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 45. Australia Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 46. South America, Middle East and Africa Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 47. South America, Middle East and Africa Conjugate Vaccine Sales Market Share by Country (2021-2032) Figure 48. Brazil Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 49. South Africa Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 50. Saudi Arabia Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 51. Turkey Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 52. Argentina Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 53. UAE Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 54. Egypt Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 55. Chile Conjugate Vaccine Sales and Growth Rate (2021-2032) & (Million Unit) Figure 56. Global Conjugate Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Conjugate Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. North America Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Europe Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Conjugate Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Conjugate Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Hib Vaccine
  • Meningococcal Vaccine
  • Pneumococcal Vaccine
  • Others
Applications
  • Children
  • Adult
Companies covered
  • Pfizer
  • GSK
  • Sanofi
  • Merck
  • Walvax Biotechnology
  • Royal (Wuxi) Bio-Pharmaceutical
  • Bharat Biotech
  • Zhifei Biologic

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Conjugate Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Conjugate Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Conjugate Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Conjugate Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Conjugate Vaccine Market Dynamics
  1. 2.1 Conjugate Vaccine Industry Trends
  2. 2.2 Conjugate Vaccine Industry Drivers
  3. 2.3 Conjugate Vaccine Industry Opportunities and Challenges
  4. 2.4 Conjugate Vaccine Industry Restraints
3 Conjugate Vaccine Market by Manufacturers
  1. 3.1 Global Conjugate Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Conjugate Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Conjugate Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Conjugate Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Conjugate Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Conjugate Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Conjugate Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Conjugate Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Conjugate Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Conjugate Vaccine Tier 1, Tier 2, and Tier 3
4 Conjugate Vaccine Market by Type
  1. 4.1 Conjugate Vaccine Type Introduction
  2. 4.1.1 Hib Vaccine
  3. 4.1.2 Meningococcal Vaccine
  4. 4.1.3 Pneumococcal Vaccine
  5. 4.1.4 Others
  6. 4.2 Global Conjugate Vaccine Sales by Type
  7. 4.2.1 Global Conjugate Vaccine Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Conjugate Vaccine Sales by Type (2021-2032)
  9. 4.2.3 Global Conjugate Vaccine Sales Market Share by Type (2021-2032)
  10. 4.3 Global Conjugate Vaccine Revenue by Type
  11. 4.3.1 Global Conjugate Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Conjugate Vaccine Revenue by Type (2021-2032)
  13. 4.3.3 Global Conjugate Vaccine Revenue Market Share by Type (2021-2032)
5 Conjugate Vaccine Market by Application
  1. 5.1 Conjugate Vaccine Application Introduction
  2. 5.1.1 Children
  3. 5.1.2 Adult
  4. 5.2 Global Conjugate Vaccine Sales by Application
  5. 5.2.1 Global Conjugate Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Conjugate Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Conjugate Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Conjugate Vaccine Revenue by Application
  9. 5.3.1 Global Conjugate Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Conjugate Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Conjugate Vaccine Revenue Market Share by Application (2021-2032)
6 Global Conjugate Vaccine Sales by Region
  1. 6.1 Global Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Conjugate Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Conjugate Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Conjugate Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Conjugate Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Conjugate Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Conjugate Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Conjugate Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Conjugate Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Conjugate Vaccine Revenue by Region
  1. 7.1 Global Conjugate Vaccine Revenue by Region
  2. 7.1.1 Global Conjugate Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Conjugate Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Conjugate Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Conjugate Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Conjugate Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Conjugate Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Conjugate Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Conjugate Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Conjugate Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Pfizer
  2. 8.1.1 Pfizer Company Information
  3. 8.1.2 Pfizer Business Overview
  4. 8.1.3 Pfizer Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Pfizer Conjugate Vaccine Product Portfolio
  6. 8.1.5 Pfizer Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GSK Conjugate Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Conjugate Vaccine Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck Conjugate Vaccine Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Walvax Biotechnology
  26. 8.5.1 Walvax Biotechnology Company Information
  27. 8.5.2 Walvax Biotechnology Business Overview
  28. 8.5.3 Walvax Biotechnology Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Walvax Biotechnology Conjugate Vaccine Product Portfolio
  30. 8.5.5 Walvax Biotechnology Recent Developments
  31. 8.6 Royal (Wuxi) Bio-Pharmaceutical
  32. 8.6.1 Royal (Wuxi) Bio-Pharmaceutical Company Information
  33. 8.6.2 Royal (Wuxi) Bio-Pharmaceutical Business Overview
  34. 8.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product Portfolio
  36. 8.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments
  37. 8.7 Bharat Biotech
  38. 8.7.1 Bharat Biotech Company Information
  39. 8.7.2 Bharat Biotech Business Overview
  40. 8.7.3 Bharat Biotech Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bharat Biotech Conjugate Vaccine Product Portfolio
  42. 8.7.5 Bharat Biotech Recent Developments
  43. 8.8 Zhifei Biologic
  44. 8.8.1 Zhifei Biologic Company Information
  45. 8.8.2 Zhifei Biologic Business Overview
  46. 8.8.3 Zhifei Biologic Conjugate Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Zhifei Biologic Conjugate Vaccine Product Portfolio
  48. 8.8.5 Zhifei Biologic Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Conjugate Vaccine Value Chain Analysis
  2. 9.1.1 Conjugate Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Conjugate Vaccine Production Mode & Process
  6. 9.2 Conjugate Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Conjugate Vaccine Distributors
  9. 9.2.3 Conjugate Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst